US 12,371,504 B2
Trispecific proteins and methods of use
Holger Wesche, San Francisco, CA (US); Bryan D. Lemon, Mountain View, CA (US); and Richard J. Austin, San Francisco, CA (US)
Assigned to Harpoon Therapeutics, Inc., South San Francisco, CA (US)
Filed by HARPOON THERAPEUTICS, INC., South San Francisco, CA (US)
Filed on Sep. 14, 2021, as Appl. No. 17/475,216.
Application 17/475,216 is a continuation of application No. 16/159,554, filed on Oct. 12, 2018, granted, now 11,136,403.
Claims priority of provisional application 62/572,381, filed on Oct. 13, 2017.
Prior Publication US 2022/0112297 A1, Apr. 14, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/18 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 39/395 (2013.01); A61P 35/00 (2018.01); C07K 16/18 (2013.01); C07K 16/2809 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01); C07K 2319/31 (2013.01)] 25 Claims
 
1. A method for treating a cancer in a human subject having the cancer, comprising administering to the subject a pharmaceutical composition comprising a B cell maturation agent (BCMA) binding trispecific protein that comprises:
(a) a first domain (A) which is a single chain variable fragment (scFv) that specifically binds to a human CD3ε;
(b) a second domain (B) which is a single domain antibody that specifically binds to a human serum albumin protein; and
(c) a third domain (C) which is a single domain antibody that specifically binds to a human BCMA comprising the sequence of SEQ ID NO: 468,
wherein the third domain comprises complementarity determining regions CDR1, CDR2, and CDR3,
wherein the CDR1 comprises the amino acid sequence of SEQ ID NO: 76, the CDR2 comprises the amino acid sequence of SEQ ID NO: 190, and the CDR3 comprises the amino acid sequence of SEQ ID NO: 304, and
wherein the cancer expresses BCMA.